Q3 EPS Forecast for BioMarin Pharmaceutical Cut by Analyst

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Research analysts at Leerink Partnrs dropped their Q3 2025 earnings estimates for shares of BioMarin Pharmaceutical in a research report issued on Wednesday, October 8th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings of ($0.34) per share for the quarter, down from their previous estimate of $0.78. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical’s Q4 2025 earnings at $0.80 EPS, FY2025 earnings at $2.67 EPS, Q3 2026 earnings at $0.89 EPS, Q4 2026 earnings at $0.91 EPS, FY2026 earnings at $3.54 EPS and FY2027 earnings at $5.14 EPS.

Several other equities research analysts also recently weighed in on the stock. UBS Group boosted their target price on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Zacks Research downgraded shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Wall Street Zen lowered shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday. HC Wainwright began coverage on shares of BioMarin Pharmaceutical in a report on Monday, September 8th. They issued a “neutral” rating and a $60.00 price target for the company. Finally, Raymond James Financial began coverage on shares of BioMarin Pharmaceutical in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $85.00 price target for the company. Thirteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $93.26.

BioMarin Pharmaceutical Price Performance

BMRN opened at $52.45 on Monday. The company has a 50-day moving average of $56.21 and a 200-day moving average of $57.86. The company has a market capitalization of $10.07 billion, a P/E ratio of 15.56, a PEG ratio of 0.70 and a beta of 0.33. BioMarin Pharmaceutical has a 1-year low of $51.78 and a 1-year high of $73.51. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 5.56.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BMRN. Farther Finance Advisors LLC boosted its stake in BioMarin Pharmaceutical by 95.9% during the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 211 shares during the period. GAMMA Investing LLC boosted its stake in BioMarin Pharmaceutical by 154.0% during the 1st quarter. GAMMA Investing LLC now owns 3,129 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 1,897 shares during the period. Integrated Advisors Network LLC boosted its stake in BioMarin Pharmaceutical by 28.0% during the 1st quarter. Integrated Advisors Network LLC now owns 4,000 shares of the biotechnology company’s stock valued at $283,000 after purchasing an additional 876 shares during the period. Fifth Third Bancorp boosted its stake in BioMarin Pharmaceutical by 76.2% during the 1st quarter. Fifth Third Bancorp now owns 2,381 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 1,030 shares during the period. Finally, NorthCrest Asset Manangement LLC acquired a new position in BioMarin Pharmaceutical during the 1st quarter valued at about $345,000. 98.71% of the stock is owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.